14 DAY TRIAL // This October's issue of Oncology Reports witnessed the publication of a new study stating that a mixture of medicinal mushrooms, traditional Chinese herbs and other natural ingredients can help fight back the aggressiveness of triple-negative breast and breast-to-lung metastasis.
The researchers who looked into this issue came up with a formula encompassing various types of medicinal mushrooms and herbs, and used it to treat laboratory mice that were suffering from said diseases.
Apparently, most of these mice got better after being administered this formula, and the scientists now claim that this is because the medicinal mushrooms work towards reducing cancer growth and invasiveness.
Meanwhile, the herbs see to it that programmed cell death is induced and thus help reduce metastasis.
Newswise reports that, as far as these laboratory mice were concerned, the total accounts of metastasis were reduced from 70% in the case of those left untreated to just 20% in the case of those which were introduced to the mushrooms and herbs mixture.
For the time being, triple-negative breast cancer is considered to be a highly aggressive form of cancer, and those who happen to be diagnosed with it are known to go on living for considerably shorter amounts of time than those who have other forms of this disease.
Commenting on the findings of this investigation, co-author Isaac Eliaz, M.D., made a case of how, “Patients with triple-negative breast cancer often die from metastasis.”
However, “This formula may be an important adjunct in treating the most aggressive type of breast cancer and other forms of this disease. It dramatically decreases the metastatic process, slows the growth of primary tumors and favorably alters oncogene expression.”
Interestingly enough, it seems that, unlike other types of treatment, this mixture of mushrooms and herbs does not leave the patient suffering from any noteworthy side effects.
Given the fact that these experiments carried out on mice proved to be quite successful, it is to be expected that a clinical trial involving human subjects will be up and running as early as the year 2013.